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and Renato Fanin
ABGG2 protein overexpression in acute myeloid leukemia (AML) has been associated with poor response to
conventional chemotherapy and increased relapse risk. No data are available on the role of allogeneic stem
cell transplantation (SCT) in reversing its negative prognostic role. We have reviewed the outcome of 142
patients with high risk AML who underwent allogeneic SCT in complete remission (n = 94) or with active
disease (n = 48). Patients with ABCG2 overexpression at AML diagnosis have lower leukemia free survival
(LFS) and increased cumulative incidence of relapse (CIR) compared with ABCG22 patients (5-year LFS 50%
vs. 65%, P = 0.01; 5-year CIR 46% vs. 27%, P = 0.003). Five-year overall survival was not significantly different
between ABCG21 and ABCG22 patients (39% vs. 51%, P = 0.1). However, if we consider only disease-related
deaths, ABCG2 maintains its negative role (64% vs. 78%, P = 0.018). The negative impact of ABCG2
overexpression was higher in patients undergoing SCT in CR compared with patients receiving transplant
with active disease. Conditioning regimen did not abrogate the effect of ABCG2 overexpression, as CIR was
higher in ABCG21 patients receiving both myeloablative (44% vs. 22%, P = 0.018) or reduced intensity
conditioning (50% vs. 32%, P = 0.03). In conclusion, ABCG2 overexpression at AML diagnosis identifies a
subset of patients with poor outcome also after allogeneic SCT, mainly in terms of higher relapse rates.
Prospective studies employing conditioning drugs or post-transplant strategies able to target ABCG2 are
needed to maximize the curative potential of stem cell transplantation.
Am. J. Hematol. 90:784–789, 2015. VC 2015 Wiley Periodicals, Inc.
 Introduction
Acute myeloid leukemia (AML) is a heterogeneous clonal disorder of hematopoietic progenitors, which, as a consequence of various genetic
mutations, lose their maturation capacity and acquire proliferative advantage, thus resulting in accumulation of immature, nonfunctional cells in
bone marrow and peripheral blood.
Despite in the past three decades significant improvements were made in the knowledge of leukemia pathogenesis, prognostic factors, drugs’
availability and in patients care, the overall prognosis of AML remains poor, and estimated 5-year overall survival (OS) after standard dose chemo-
therapy is 38% [1,2]. In elderly patients efficacy of conventional chemotherapy is even lower, with OS around 10% 5 years after diagnosis [1,3,4].
So, allogeneic stem cell transplantation (SCT) is considered the recommended postinduction therapy [5–7]. The advent of reduced intensity condi-
tioning (RIC) regimens, and the increased availability of alternative donors have widened the number of patients that may benefit from SCT,
changing the treatment algorithm of intermediate and high risk patients [8,9]. Unfortunately, relapse still occurs in a consistent part of patients
and remains the major cause of treatment failure after allogeneic SCT [10–12]. Therefore, efforts have been focused on the identification of factors
that can predict disease recurrence and on strategies to possibly prevent it. Pretreatment cytogenetic alterations and molecular abnormalities, such
as FLT3 gene mutations, are associated with increased incidence of relapse [13–15], even if mechanisms underlying this risk remain largely
unknown. In the last years, various studies had found that overexpression of multidrug resistance protein ABCG2 confer resistance to many differ-
ent chemotherapeutic agents [16,17], and that ABCG2 overexpression is associated with a worse prognosis in AML patients [18–20]. No informa-
tion is available on the impact of ABCG2 in patients undergoing allogeneic SCT for AML.
We have retrospectively evaluated 142 patients who underwent allogeneic SCT for AML, with the aim to clarify the ability of preparative regi-
mens and of the new immune system to abrogate the negative prognosis associated with ABCG2 expression.
 Materials and Methods
Patients. We reviewed our database of patients and identified 142 patients who underwent allogeneic SCT for high risk AML between 2001 and 2013 at the Division of
Hematology of Udine. Cytogenetic risk group assignment was done according to the 2010 revised MRC criteria [21]. Multidrug resistance associated proteins expression on
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blast cells at diagnosis were evaluated by flow cytometry as previously described
[19]. Cases with mean fluorescence intensity above the identified cut-off were con-
sidered “over-expressing” and referred as “positive” in the text.
All patients received induction chemotherapy according to the protocol in use
at the time of diagnosis and at least one consolidation course of chemotherapy with
high-dose cytarabine and idarubicin.
Patients’ and transplant’s characteristics are summarized in Table I. Indications
to SCT included high-risk features at diagnosis (i.e. high blast count, unfavorable
karyotype, secondary AML), late complete remission (CR) achievement, primary
resistance or disease relapse. EBMT score was used to define transplant risk.
Median age was 49 years (range, 17–69 years) and 65/142 (45%) were older
than 50 years and 28 patients (20%) were over 60 years. Thirty-one out of 142
(22%) patients had secondary AML, 51 (36%) had WBC count >30 3 109/L, 30/
142 (21%) had an unfavorable cytogenetics, and 59/142 (41%) overexpressed one or
more MDR proteins. Thirty-eight patients (27%) did not achieve CR after induction
chemotherapy. Fifty-six (39%) had an high-risk EBMT score (>4).
Sixty-six patients (46%) received stem cells from an HLA identical sibling, 69
(49%) from a matched unrelated donor and 7 (5%) from a haploidentical donor.
Twenty-five of 142 (18%) were males with a female donor; stem cell source was
bone marrow in 48 patients (34%), peripheral blood in 94 patients (66%). Condi-
tioning regimen was myeloablative in 88/142 (62%) cases, while 54 patients (38%)
received a reduced-intensity conditioning (RIC) (Supporting Information Table I).
Graft-versus-host disease (GVHD) prophylaxis consisted of a calcineurin inhibitor
(cyclosporine or tacrolimus) combined with methotrexate, with or without anti-
thymocyte globulin (ATG); rapamycin and micofenolate mofetil were used accord-
ing to the protocol in use at time of RIC transplant. Supportive care for all patients
followed institutional standards.
Definitions and statistical analysis. CR was defined as peripheral blood normal-
ization and absence of bone marrow minimal residual disease by morphological,
molecular or immunophenotypic evaluation. Leukemia free survival (LFS) was
defined as survival without evidence of disease recurrence or progression from
transplant. Overall survival (OS), defined as time from date of transplantation to
death, independently of the cause. Nonrelapse mortality (NRM) was defined as
death without prior relapse.
Statistical analyses were performed by the NCSS 8 software package (NCSS,
LLC, Kaysville, UT; available at: www.ncss) and by EZR package [22] in presence
of competing risks. Patient-, disease-, and transplant-related categorical variables
were compared by v2 test. Survival curves were obtained by Kaplan-Meier method
and differences between groups compared by log-rank test. Hazard ratios for LFS
and OS were determined by Cox regression analysis [23]. Cumulative incidence of
relapse (CIR) was calculated by Gray’s method considering NRM as competing risk
[24]. Multivariate analysis was performed for factors with statistical significance or
borderline significance (P< 0.1) using Fine-Gray proportional hazard regression for
competing events [25]. All P values are two-sided with type I error fixed at 0.05.
 Results
Transplant procedure
Ninety-four out of 142 patients (66%) underwent transplant in first
or second CR, at a median of 7 months (range, 3–179 months) from
diagnosis. Forty-eight patients (34%) received HSCT with evidence of
leukemia, as defined either by morphological and/or cytogenetic/
molecular evaluation.
Neutrophil (absolute neutrophil count >1 3 109/L without G-
CSF) and platelet (platelets >20 3 109/L without transfusions) were
attained after a median 19 (range, 17–23) and 20 (range, 14–35) days,
respectively. Acute GVHD occurred in 70/142 patients (49%), but in
only 16/70 (23%) was of grade 3, without differences between donor
type or stem cell source. Chronic GVHD was evaluable in 108/142
patients (76%). Fifty-one (47%) developed cGVHD, that was extensive
in 10 (20%). Microbiological documented pre-engraftment infections
occurred in 61/142 patients (43%): Gram1 sepsis in 28 patients,
Gram2 sepsis in 18 patients, pneumonia in 25 (bacterial, n = 21 or
fungal, n = 4) patients; CMV reactivation occurred in 23 cases. Post-
engraftment infections occurred in 49 patients, and were mainly of
viral etiology (30 CMV reactivation, 8 EBV reactivation, 6 HZV
infection, and 1 HBV hepatitis). Severe noninfective post-transplant
complications included hemorrhagic cystitis (n = 13), congestive heart
failure (n = 6), veno-occlusive disease (n = 3), and acute pericarditis
(n = 2).
Outcomes: Univariate analysis
Leukemia free survival. At the time of the analysis, 83/142
(58.4%) patients were alive and in CR, with a cumulative 5-year LFS
of 56% (95% confidence interval [CI], 47–65%). Factors affecting LFS
are listed in Table II. Among transplant related factors, a negative
association was observed only with unrelated donor (52%; 95% CI,
38–64%) compared with sibling donor (65%; 95% CI, 53–77%) (P =
0.03), and with the absence of chronic GVHD (53%; 95% CI, 40–66%
vs. 84%; 95% CI, 73–95%; P = 0.001). With regard to disease charac-
teristics, the persistence of leukemia at SCT was associated with
reduced LFS: 30% (95% CI, 16–46%) versus 72% (95% CI, 67–82%)
in patients transplanted in CR (P < 0.0001). Unfavorable cytogenetics
(32%; 95% CI, 12–51%, vs. 67%; 95% CI, 57–77% in intermediate-
risk and 67%; 95% CI, 34–97% in favorable-risk groups; P = 0.01),
and ABCG2 overexpression at diagnosis (50%; 95% CI, 37–64% vs.
65%; 95% CI, 53–76%, in negative patients; P = 0.01) were associated
with shorter LFS (Fig. 1a).
Cumulative incidence of relapse (CIR) and cumulative incidence of
nonrelapse mortality (CIRNM). As shown in Table II, considering
transplant factors only chronic GVHD has a protective effect on
relapse risk (P = 0.014). However, the ability of chronic GVHD to
exert a GVL effect was particularly evident in the ABCG2-negative
group (CIR: 10%, 95% CI, 4–31% in presence of cGVHD and 46%,
95% CI, 33–64% in patients without cGVHD, P = 0.001) (Supporting
Information Fig. 1). Conversely only a trend in lower relapse rate was
observed in ABCG2-positive patients (P = 0.18) (Supporting Informa-
tion Fig. 1). Nonsignificant risk factors included donor/recipient com-
patibility, donor type, stem cell source and dose, conditioning
TABLE I. Patients and Transplant Characteristics
n5 142
Age (yrs)
Median (range) 49 (17–69)
>50 65 (45%)
Sex
M 67
F 75
Secondary AML 42 (29%)
Cytogenetics
Favorable 10 (7%)
Intermediate 96 (67%)
Unfavorable 30 (21%)
Missing 6 (4%)
WBC >30 3 109/L 51 (36%)
MDR proteins expression 59 (41%)
Late CR 38 (27%)
Disease status at transplant
CR 94(66%)
No CR 48(34%)
Donor type
Sibling 64 (45%)
Unrelated 78 (55%)
Compatibility
Full-matched 81 (57%)
Mis-matched 61 (43%)
Female donor/male recipient
No 117 (82%)
Yes 25 (18%)
Stem cell source: bone marrow 47 (33%)
Peripheral blood 95 (67%)
Stem cell dose
4 x 106/kg 70 (49%)
<4 x 106/kg 74 (51%)
Conditioning regimen
Myeloablative 88 (62%)
Reduced intensity 54 (38%)
MDR: multidrug resistance.
RESEARCH ARTICLE ABCG2 and Allogeneic SCT in AML
doi:10.1002/ajh.24084 American Journal of Hematology, Vol. 90, No. 9, September 2015 785
regimens and acute GVHD. Advanced recipient’s age has a trend for
a higher risk of relapse (P = 0.07). Five-year CIR was significantly
higher in patients with AML persistence at SCT (59%; 95% CI, 44–
71%), unfavorable karyotype (55%; 95% CI, 34–71%), and ABCG2
positivity (46%; 95% CI, 33–58%) (Fig. 1b). The negative impact of
ABCG2 overexpression was particularly evident in the cohort of
patients transplanted while in CR: 5-year CIR was 32% (95% CI, 19–
51%) in ABCG21 compared with 15% (95% CI, 8%-27%) in
ABCG22 patients (P = 0.02; Fig. 1c). Conversely, in patients under-
going allogeneic SCT with active AML, difference in CIR between
ABCG21 (67%; 95% CI, 50–88%) and ABCG22 cases (52%; 95% CI,
36–74%), did not reach statistical significance (P = 0.09; Fig. 1d). The
higher relapse rate associated with high ABCG2 overexpression was
not influenced by conditioning regimen: CIR after myeloablative SCT
was 44% (95% CI, 28–59%) in ABCG21 and 22% (95% CI 12–35%)
in ABCG2-negative group (P = 0.018); after RIC SCT, CIR was 50%
(95% CI, 25–71%) in ABCG21 and 32% (95% CI, 17–31%) in
ABCG22 patients, respectively (P = 0.03).
ABCG2 expression did not influence NRM: 5-year CINRM was
23% (95% CI, 14–33%) in ABCG2-positive patients, compared with
15% (95% CI, 8%-24%) in negative ones (P = 0.08). CINRM was
affected by donor type (unrelated 26% vs. sibling 12%, P = 0.03),
HLA compatibility (mismatched 30%, in vs. matched 15%, P = 0.03),
conditioning regimen (RIC 32% vs. MAC 12%, P = 0.013) and devel-
opment of acute GVHD (50% vs. 16%, P = 0.003) or chronic GHVD
(23% vs. 9%, P = 0.01).
Overall survival. At the time of this analysis, 61/142 (43%)
patients were alive, 41 (29%) died of AML recurrence and 40 (28%)
died from NRM. One-year OS was 62% (95% CI, 54–70%) and 46%
patients (95% CI, 38–55%) were alive 5 years after SCT. Five-year OS
was higher in patients younger than 50 years (54%; 95% CI, 41–67%)
compared with elderly ones (38%; 95% CI, 26–50%; P = 0.05), in
patients receiving SCT while in CR (63%; 95% CI, 53–74% vs. 15%;
95% CI, 5–25%; P < 0.0001), in recipient of transplant from siblings
(58%; 95% CI, 43–71% vs. 35%; 95% CI, 42–46%; P = 0.0004) and
from full matched donors (50%; 95% CI, 38–62% vs. 33%; 95% CI,
19–47%; P = 0.02) and in patients receiving myeloablative condition-
ing (55%; 95% CI, 44–66% vs. 30%; 95% CI, 16–4%; P = 0.003).
Though ABCG2 overexpression did not influence OS, if we consider
only disease-related deaths 5-year survival rate was significantly lower
in ABCG21 patients (64%; 95% CI, 50–74%) compared with
ABCG22 ones (78%; 95% CI, 66–85%; P = 0.018).
Outcomes: Multivariate analysis
Results of multivariate analysis on the different outcomes are sum-
marized in Table III. By Cox proportional hazard regression, age >50
years (HR =2.32; 95% CI, 1.1–5.0%), unfavorable cytogenetics
(HR5 2.01; 95% CI, 1.04–3.85%), high ABCG2 expression at
TABLE II. Univariate Analysis of Factors Affecting SCT Outcome
5-year LFS 5-year OS 5-year CIR 5-year NRM
Variable %(95% CI) P %(95% CI) P %(95% CI) P %(95% CI) P
Age
<50 66(54–78) 0.22 54(41–67) 0.05 41(30–52) 0.07 21(13–31) 0.23
50 52(10–64) 38(26–50) 27(16–38) 18(9–28)
Cytogenetics
Favorable 67(34–97) 0.01 50(19–81) 0.13 30(6–59) 0.02 30(6–60) 0.20
Intermediate 67(57–77) 51(40–62) 27(19–36) 21(14–30)
Unfavorable 32(12–51) 33(15–51) 55(34–71) 10(2–24)
ABCG2
Positive 50(37–64) 0.01 39(23–49) 0.10 46(33–58) 0.003 15(7–26) 0.08
Negative 65(53–76) 51(39–63) 27(18–37) 23(14–33)
Disease status at SCT
CR 72(67–82) <0.0001 63(53–74) <0.0001 21(13–30) 0.0002 18(10–27) 0.70
No CR 30(16–46) 15(5–25) 59(44–71) 23(13–36)
Donor type
SIB 65(53–77) 0.03 58(43–71) 0.0004 30(19–41) 0.10 12(5–22) 0.03
URD 52(38–64) 35(42–46) 39(28–49) 26(17–36)
HLA matching
Full match 59(48–70) 0.23 50(38–62) 0.02 35(24–45) 0.35 15(8–24) 0.03
Mismatch 37(22–52) 33(19–47) 42(27–55) 30(17–43)
Female donor to male recipient
No 55(46–65) 0.55 44(34–54) 0.46 36(27–45) 0.90 21(14–29) 0.41
Yes 71(54–89) 54(34–74) 28(12–46) 19(5–39)
Conditioning
MAC 66(52–80) 0.17 55(44–66) 0.003 33(23–43) 0.43 12(6–20) 0.013
RIC 51(36–67) 30(16–43) 37(25–51) 32(30–46)
Stem cell source
BM 61(47–76) 0.45 52(37–66) 0.39 34(30–55) 0.70 17(8–30) 0.62
PB 57(45–68) 42(31–53) 35(26–45) 22(14–32)
Stem cell dose
<4 3 106/kg 51(38–64) 0.22 43(30–55) 0.30 43(30–55) 0.21 16(8–27) 0.66
4 3 106/kg 63(50–75) 50(37–63) 30(20–41) 18(10–28)
Acute GVHD
No 59(46–72) 0.44 56(43–70) 0.18 32(24–41) 0.42 16(10–24) 0.003
Yes 67(56–79) 40(25–51) 25(7–49) 50(23–72)
Chronic GVHD
No 53(40–66) 0.001 57(43–70) 0.34 41(28–53) 0.001 9(3–19) 0.01
Yes 84(73–95) 59(44–74) 12(4–24) 23(11–38)
SCT5stem cell transplantation; LFS5 leukemia free survival; OS5overall survival; CIR5 cumulative incidence of relapse; NRM5nonrelapse mortality;
URD5 unrelated donor; SIB5 sibling donor; MAC5myeloablative conditioning; RIC5 reduced intensity conditioning; BM5bone marrow; PB5peripheral
blood; GCVH5graft versus host disease.
Values in bold are statistical significant.
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diagnosis (HR5 2.32; 95% CI, 1.12–4.76%), and disease persistence at
SCT (HR5 3.69; 95% CI, 1.85–7.35%) are independently associated
with poor LFS. Conversely, a benefit for LFS was seen in patients
developing chronic GVHD (HR5 0.28; 95% CI, 0.13–0.61%).
Advanced age (HR5 2.17; 95% CI, 1.19–3.84%) and no CR at
transplant (HR5 4.63; 95% CI, 2.66–8.05%) confirmed their negative
impact also on OS. A higher risk of death was observed also in recip-
ients of unrelated donor SCT (HR5 2.42; 95% CI, 1.14–5.15%).
As for LFS, older age (HR5 0.36; 95% CI, 0.16–0.80%), ABCG2
positivity (HR5 0.32; 95% CI, 0.15–0.71%), no CR at transplant
(HR5 0.50; 95% CI, 0.33–0.76%) and chronic GVHD (HR5 0.28;
95% CI, 0.12–0.66%) were associated with a higher incidence of
relapse. Development of chronic GVHD was the only factor signifi-
cantly associated with an increased risk of NRM (HR5 1.85; 95% CI,
1.02–3.35%).
 Discussion
The ultimate challenge in allogeneic SCT for high-risk AML is to
prevent relapse, eradicating the leukemic stem cell population, with-
out increasing procedure-related toxicity. In the past years efforts
have been focused on discovering factors affecting disease recurrence
after transplant. It is well known that an important role is played by
cytogenetic abnormalities present at diagnosis [13,14] and by some
molecular markers in the subset of cytogenetically normal AML [15].
In the present work we evaluated factors affecting long-term out-
comes in a series of 142 patients receiving allogeneic SCT in complete
remission or with active leukemia. Among transplant-related charac-
teristics, only the development of chronic GVHD and the availability
of a sibling donor were associated with better OS and LFS,
Figure 1. Leukemia free survival (a) and cumulative incidence of relapse in the whole population (b) according to ABCG2 expression. Cumulative incidence
of relapse in patients underwent SCT in CR (c) and with active disease (d) according to expression of ABCG2.
TABLE III. Multivariate Analysis of Prognostic Factors for LFS, OS, CIR, and
NRM
Variable HR 95% CI P
LFS
Age >50 yr 2.32 1.10–5.0 0.02
Unfavorable cytogenetics 2.01 1.04–3.85 0.03
ABCG2 positive 2.32 1.20–4.76 0.02
No CR at SCT 3.69 1.85–7.35 0.0002
Unrelated donor 1.62 0.81–3.21 0.16
Chronic GVHD 0.28 0.13–0.61 0.001
OS
Age >50 yr 2.17 1.19–3.84 0.01
ABCG2 positive 1.23 0.73–2.08 0.43
No CR at SCT 4.63 2.66–8.05 <0.0001
Unrelated donor 2.42 1.14–5.15 0.02
Full HLA matching 1.05 0.53–2.07 0.88
Myeloablative conditioning 1.04 0.54–1.71 0.89
CIR
Age >50 yr 2.77 1.25–6.25 0.01
Unfavorable cytogenetics 1.84 0.78–4.36 0.16
ABCG2 positive 3.12 1.40–7.14 0.005
No CR at SCT 1.99 1.31–3.02 0.001
Chronic GVHD 0.28 0.12–0.66 0.004
NRM
ABCG2 positive 1.20 0.39–3.70 0.75
Unrelated donor 1.44 0.41–5.04 0.57
Full HLA matching 0.99 0.17–5.55 0.99
Myeloablative conditioning 2.35 0.73–7.50 0.15
Acute GVHD 1.10 0.17–7.12 0.92
Chronic GVHD 1.85 1.02–3.35 0.04
SCT5stem cell transplantation; LFS5 leukemia free survival; OS5overall
survival; CIR5 cumulative incidence of relapse; NRM5nonrelapse mortal-
ity; GVHD5graft versus host disease.
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respectively. Considering pretransplant factors, AML status and
unfavorable cytogenetic remain the stronger predictors, in line with
previous literature data [26–28]. The most important novel finding
emerging from our data is the negative role of ABCG2 overexpression
on SCT outcome. Many authors have associated the overexpression
of different members of ABC proteins with resistance to conventional
induction chemotherapy in AML[18,19,29] but, till now, no data are
available on the role of ABCG2 level at AML diagnosis in patients
undergoing allogeneic SCT. We found that patients with high ABCG2
expression have a shorter LFS rate compared with ABCG2-negative
ones (50% vs. 65 at 5 years after SCT). The unfavorable impact of
ABCG2 was confirmed by the higher rate of CIR in ABCG2-positive
patients (46% at 5 years). Of note, the correlation between ABCG2
positivity and higher relapse risk was statistically significantly only in
patients who underwent SCT while in CR, as if in patients trans-
planted with active AML the kinetics of disease growth under immu-
nosuppressive therapy would predominate on the reduced drug
sensitivity mediated by ABC transporter proteins. The negative role
of ABCG2 is retained in the multivariate model, with a risk of relapse
three times higher in ABCG21 patients. Moreover, ABCG2-mediated
drug extrusion is only one of many mechanisms used by leukemic
cells to survive to chemotherapy, but our findings suggest that the
management of high-risk AML and the efforts to prevent disease
relapse should consider the role of ABCG2. Many reports on solid
tumors have recently underlined that ABCG2 is implicated not only
in inducing drug resistance in the proliferating pool, but confers to
blasts the characteristics of a stem cell-like population, surviving after
therapy as a “disease reservoir.” We hypothesizes that ABCG2 overex-
pression in the whole leukemic population is associated with higher
number of more immature ABCG21 cells closely correlated with the
so-called “side population,” that seems to be involved not only in the
initiation but also in progression and relapse of acute leukemia, and
that may be able to survive after SCT despite conditioning chemo-
therapy and transplant-related immune control [29–35]. Laboratory
studies are currently ongoing to prove this hypothesis.
Prospective studies are needed to investigate the possibility to erad-
icate the leukemic stem cell (LSC) compartment by modulating con-
ditioning regimens. Many new tyrosine kinase inhibitors are able to
inhibit ABCG2 activity or to favor its degradation via lysosome, ulti-
mately reversing LSCs properties [36–43]. Also epigenetic regulation
of ABCG2 expression has been recently proposed as a cause of poor
response to new chemotherapeutic agents. Bram et al. observed that
drug-induced ABCG2 promoter demethylation is responsible for a
new form of acquired drug resistance [44]. This observation is of par-
ticular importance in the post-transplant setting, since hypomethylat-
ing drugs have been used to improve outcome on the basis that
hypomethylating agents up-regulate anti-tumor CD81 T-cell
response, limiting at the same time the risk of GVHD by accelerating
CD41 Treg recovery [45–47]. However, Craddock et al. have recently
reported that azacytidine (AZA) fails to eradicate the stem/progenitor
population in acute leukemia [48]. A possible explanation could be
that DNA-demethylation induced by AZA promotes ABCG2 expres-
sion, thus increasing bone marrow LSCs reservoir.
In conclusion, our data outline the negative role played by ABCG2
overexpression in AML receiving allogeneic SCT. Although the
impact of MDR-related proteins in affecting response to induction
chemotherapy and LFS has been recognized for 20 years, to date no
significant therapeutic changes have been made. In this era of techno-
logical explosion and of new “target drugs,” recognition of the nega-
tive role of ABCG2 may help in designing post-transplant strategies
to maximize the curative potential of SCT for acute leukemia.
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